Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR445399 versus placebo in adults with non-cystic fibrosis bronchiectasis
NL-OMON61306Phase 2Not yet recruiting
- Sponsor
- Sanofi
- Start
- Aug 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in bronchiectasis comparing SAR445399 with Placebo (2 arms). Primary endpoint: Change from baseline to Week 24 in mucus plug score. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
SAR445399
03
Conditions
bronchiectasis
Beyond the preview
Go deeper on NL-OMON61306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61306.